News
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
ICON plc to Present at the Baird Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual